Anti-atherogenic Modification of Serum Lipoprotein Function in Patients with Rheumatoid Arthritis after Tocilizumab Treatment, a Pilot Study

Lipid metabolism derangement contributes to increased cardiovascular risk in Rheumatoid Arthritis (RA). It is still debated whether and how tocilizumab, an interleukin-6 receptor inhibitor used in active RA, impacts cardiovascular risk. We studied the effect of tocilizumab on the regulation of macro...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Daniela Greco, Roberta Gualtierotti, Pasquale Agosti, Maria Pia Adorni, Francesca Ingegnoli, Matteo Rota, Franco Bernini, Pier Luigi Meroni, Nicoletta Ronda
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: MDPI AG 2020-07-01
Saila:Journal of Clinical Medicine
Gaiak:
cardiovascular disease
tocilizumab
rheumatoid arthritis
atherosclerosis
lipoproteins
cellular cholesterol
Sarrera elektronikoa:https://www.mdpi.com/2077-0383/9/7/2157
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak